CHRONIC MITOCHONDRIAL ENERGY IMPAIRMENT PRODUCES SELECTIVE STRIATAL DEGENERATION AND ABNORMAL CHOREIFORM MOVEMENTS IN PRIMATES

被引:388
作者
BROUILLET, E
HANTRAYE, P
FERRANTE, RJ
DOLAN, R
LEROYWILLIG, A
KOWALL, NW
BEAL, MF
机构
[1] MASSACHUSETTS GEN HOSP, DEPT NEUROL, NEUROCHEM LAB, BOSTON, MA 02114 USA
[2] CEA, DEPT RECH IMAGERIE PHARMACOL & PHYSIOL, SERV HOSP FREDERIC JOLIOT,DIRECT SCI VIVANT, CNRS, F-91401 ORSAY, FRANCE
关键词
MITOCHONDRIA; EXCITOTOXICITY; HUNTINGTON DISEASE; STRIATUM;
D O I
10.1073/pnas.92.15.7105
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Although the gene defect responsible for Huntington disease (HD) has recently been identified, the pathogenesis of the disease remains obscure. One potential mechanism is that the gene defect may lead to an impairment of energy metabolism followed by slow excitotoxic neuronal injury. In the present study we examined whether chronic administration of 3-nitropropionic acid (3-NP), an irreversible inhibitor of succinate dehydrogenase, can replicate the neuropathologic and clinical features of HD in nonhuman primates. After 3-6 weeks of 3-NP administration, apomorphine treatment induced a significant increase in motor activity as compared with saline-treated controls. Animals showed both choreiform movements, as well as foot and limb dystonia, which are characteristic of HD. More prolonged 3-NP treatment in two additional primates resulted in spontaneous dystonia and dyskinesia accompanied by lesions in the caudate and putamen seen by magnetic resonance imaging. Histologic evaluation showed that there was a depletion of calbindin neurons, astrogliosis, sparing of NADPH-diaphorase neurons, and growth-related proliferative changes in dendrites of spiny neurons similar to changes in HD. The striosomal organization of the striatum and the nucleus accumbens were spared. These findings show that chronic administration of 3-NP to nonhuman primates can replicate many of the characteristic motor and histologic features of HD, further strengthening the possibility that a subtle impairment of energy metabolism may play a role in its pathogenesis.
引用
收藏
页码:7105 / 7109
页数:5
相关论文
共 32 条
  • [21] CHOREIC MOVEMENTS IN THE MACAQUE MONKEY INDUCED BY KAINIC ACID LESIONS OF THE STRIATUM COMBINED WITH L-DOPA - PHARMACOLOGICAL, BIOCHEMICAL AND PHYSIOLOGICAL-STUDIES ON NEURAL MECHANISMS
    KANAZAWA, I
    KIMURA, M
    MURATA, M
    TANAKA, Y
    CHO, F
    [J]. BRAIN, 1990, 113 : 509 - 535
  • [22] 3-NITROPROPIONIC ACID - EXOGENOUS ANIMAL NEUROTOXIN AND POSSIBLE HUMAN STRIATAL TOXIN
    LUDOLPH, AC
    HE, F
    SPENCER, PS
    HAMMERSTAD, J
    SABRI, M
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1991, 18 (04) : 492 - 498
  • [23] LUDOLPH AC, 1992, NEURODEGENERATION, V1, P155
  • [24] GLUTAMATE BECOMES NEUROTOXIC VIA THE N-METHYL-D-ASPARTATE RECEPTOR WHEN INTRACELLULAR ENERGY-LEVELS ARE REDUCED
    NOVELLI, A
    REILLY, JA
    LYSKO, PG
    HENNEBERRY, RC
    [J]. BRAIN RESEARCH, 1988, 451 (1-2) : 205 - 212
  • [25] NEUROPATHOLOGICAL CLASSIFICATION OF HUNTINGTONS-DISEASE
    VONSATTEL, JP
    MYERS, RH
    STEVENS, TJ
    FERRANTE, RJ
    BIRD, ED
    RICHARDSON, EP
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1985, 44 (06) : 559 - 577
  • [26] 3-NITROPROPIONIC ACID IS AN INDIRECT EXCITOTOXIN TO CULTURED CEREBELLAR GRANULE NEURONS
    WELLER, M
    PAUL, SM
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY-ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY SECTION, 1993, 248 (03): : 223 - 228
  • [27] NMDA RECEPTOR LOSSES IN PUTAMEN FROM PATIENTS WITH HUNTINGTONS-DISEASE
    YOUNG, AB
    GREENAMYRE, JT
    HOLLINGSWORTH, Z
    ALBIN, R
    DAMATO, C
    SHOULSON, I
    PENNEY, JB
    [J]. SCIENCE, 1988, 241 (4868) : 981 - 983
  • [28] Zeevalk G. D., 1994, Society for Neuroscience Abstracts, V20, P1678
  • [29] EVIDENCE THAT THE LOSS OF THE VOLTAGE-DEPENDENT MG2+ BLOCK AT THE N-METHYL-D-ASPARTATE RECEPTOR UNDERLIES RECEPTOR ACTIVATION DURING INHIBITION OF NEURONAL METABOLISM
    ZEEVALK, GD
    NICKLAS, WJ
    [J]. JOURNAL OF NEUROCHEMISTRY, 1992, 59 (04) : 1211 - 1220
  • [30] ZEEVALK GD, 1990, J PHARMACOL EXP THER, V253, P1285